.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 9,206,135

« Back to Dashboard

Claims for Patent: 9,206,135

Title:Asymmetric catalytic reduction of oxcarbazepine
Abstract: A process for preparing (S)-(+)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide or (R)-(-)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide, by reduction of oxcarbazepine in the presence of a catalyst and a hydride source is disclosed. The catalyst is prepared from a combination of [RuX.sub.2(L)].sub.2 wherein X is chlorine, bromine or iodine, and L is an aryl or aryl-aliphatic ligand, with a ligand of formula (A) or formula (B): ##STR00001## wherein R.sup.1 is chosen from C.sub.1-6 alkoxy and C.sub.1-6 alkyl, n is a number from 0 to 5, and when n is a number from 2 to 5, R.sup.1 can be the same or different, and R.sup.2 is alkyl, substituted alkyl, aryl, substituted aryl, alkaryl or substituted alkaryl. The hydride source is either NR.sup.3R.sup.4R.sup.5 and formic acid, [R.sup.3R.sup.4R.sup.5NH][OOCH] and optionally formic acid, or [M][OOCH].sub.x and formic acid, wherein R.sup.3, R.sup.4 and R.sup.5 are C.sub.1-6 alkyl, M is an alkali metal or alkaline earth metal and x is 1 or 2. A pH from 6.5 to 8 is maintained during the process.
Inventor(s): Learmonth; David Alexander (Alfena, PT), Grasa; Gabriela Alexandra (Mantua, NJ), Zanotti-Gerosa; Antonio (Cambridge, GB)
Assignee: Bial-Portela & CA, S.A. (S. Mamede do Coronado, PT)
Application Number:13/651,844
Patent Claims: 1. A compound being (S)-(-)-10-acetoxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide and comprising about 2 ppm of ruthenium or less.

2. The compound of claim 1, having a chemical purity of (S)-(-)-10-acetoxy-10,11-dihydro-5H-dibenz/b,f/azepin-5-arboxamide of about 99.96%.

3. The compound of claim 1, comprising less than 2 ppm of ruthenium.

4. The compound of claim 1, obtained by a process comprising: (i) a first step comprising reducing oxcarbazepine in the presence of a catalyst and a hydride source to obtain (S)-(+)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide, wherein the catalyst is prepared from a combination of [RuX.sub.2(L)].sub.2 wherein X is chlorine, bromine or iodine, and L is an aryl or aryl-aliphatic ligand, with a ligand of formula (A) or formula (B): ##STR00010## wherein R.sup.1 is chosen from C.sub.1-6 alkoxy and C.sub.1-6 alkyl, n is a number from 0 to 5, and when n is from 2 to 5, R.sup.1 is the same or different, and R.sup.2 is alkyl, substituted alkyl, aryl, substituted aryl, alkaryl or substituted alkaryl; wherein the hydride source is chosen from NR.sup.3R.sup.4R.sup.5 and formic acid, or [R.sup.3R.sup.4R.sup.5NH][OOCH], or [R.sup.3R.sup.4R.sup.5NH][OOCH] and formic acid, or [M][OOCH].sub.x and formic acid, wherein R.sup.3, R.sup.4 and R.sup.5 are C.sub.1-6 alkyl, M is an alkali metal or alkaline earth metal and x is 1 or 2, and wherein during the process a pH from 6.5 to 8 is maintained; and (ii) a second step wherein the (S)-(+)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide is acylated.

5. The compound of claim 1, the (R)-isomer of (S)-(-)-10-acetoxy-10,1-dihydro-5H-dibenz/b,f/azepine-5-carboxamide being below the limit of detection.

6. The compound of claim 2, comprising less than 2 ppm of ruthenium.

7. The compound of claim 2, obtained by a process comprising: (i) a first step comprising reducing oxcarbazepine in the presence of a catalyst and a hydride source to obtain (S)-(+)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide, wherein the catalyst is prepared from a combination of [RuX.sub.2(L)].sub.2 wherein X is chlorine, bromine or iodine, and L is an aryl or aryl-aliphatic ligand, with a ligand of formula (A) or formula (B): ##STR00011## wherein R.sup.1 is chosen from C.sub.1-6 alkoxy and C.sub.1-6 alkyl, n is a number from 0 to 5, and when n is from 2 to 5, R.sup.1 is the same or different, and R.sup.2 is alkyl, substituted alkyl, aryl, substituted aryl, alkaryl or substituted alkaryl; wherein the hydride source is chosen from NR.sup.3R.sup.4R.sup.5 and formic acid, or [R.sup.3R.sup.4R.sup.5NH][OOCH], or [R.sup.3R.sup.4R.sup.5NH][OOCH] and formic acid, or [M][OOCH].sub.x and formic acid, wherein R.sup.3, R.sup.4 and R.sup.5 are C.sub.1-6 alkyl, M is an alkali metal or alkaline earth metal and x is 1 or 2, and wherein during the process a pH from 6.5 to 8 is maintained; and (ii) a second step wherein the (S)-(+)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide is acylated.

8. The compound of claim 2, the (R)-isomer of (S)-(-)-10-acetoxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide being below the limit of detection.

9. The compound of claim 3, having a chemical purity of (S)-(-)-10-acetoxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide of about 99.96%.

10. The compound of claim 3, obtained by a process comprising: (i) a first step comprising reducing oxcarbazepine in the presence of a catalyst and a hydride source to obtain (S)-(+)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide, wherein the catalyst is prepared from a combination of [RuX.sub.2(L)].sub.2 wherein X is chlorine, bromine or iodine, and L is an aryl or aryl-aliphatic ligand, with a ligand of formula (A) or formula (B): ##STR00012## wherein R.sup.1 is chosen from C.sub.1-6 alkoxy and C.sub.1-6 alkyl, n is a number from 0 to 5, and when n is from 2 to 5, R.sup.1 is the same or different, and R.sup.2 is alkyl, substituted alkyl, aryl, substituted aryl, alkaryl or substituted alkaryl; wherein the hydride source is chosen from NR.sup.3R.sup.4R.sup.5 and formic acid, or [R.sup.3R.sup.4R.sup.5NH][OOCH], or [R.sup.3R.sup.4R.sup.5NH][OOCH] and formic acid, or [M][OOCH].sub.x and formic acid, wherein R.sup.3, R.sup.4 and R.sup.5 are C.sub.1-6 alkyl, M is an alkali metal or alkaline earth metal and x is 1 or 2, and wherein during the process a pH from 6.5 to 8 is maintained; and (ii) a second step wherein the (S)-(+)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide is acylated.

11. The compound of claim 3, the (R)-isomer of (S)-(-)-10-acetoxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide being below the limit of detection.

12. The compound of claim 4, comprising less than 2 ppm of ruthenium.

13. The compound of claim 4, having a chemical purity of (S)-(-)-10-acetoxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide of about 99.96%.

14. The compound of claim 4, the (R)-isomer of (S)-(-)-10-acetoxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide being below the limit of detection.

15. A method of treating epilepsy comprising administering the compound of claim 1 to a patient in need thereof.

16. A method of treating epilepsy comprising administering the compound of claim 3 to a patient in need thereof.

17. A method of treating epilepsy comprising administering the compound of claim 3 to a patient in need thereof.

18. A method of treating epilepsy comprising administering the compound of claim 4 to a patient in need thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc